Search
Multiple Sclerosis Paid Clinical Trials in Minnesota
A listing of 13 Multiple Sclerosis clinical trials in Minnesota actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 13
The state of Minnesota currently has 13 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Minneapolis, Rochester, Saint Paul and Duluth.
Featured Trial
Secondary Progressive Multiple Sclerosis Study
Recruiting
Conditions:
Multiple Sclerosis(MS)
Secondary Progressive Multiple Sclerosis
Featured Trial
Relapsing Multiple Sclerosis Study
Recruiting
Conditions:
Multiple Sclerosis(MS)
Relapsing-Remitting Multiple Sclerosis
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Multiple Sclerosis Study
Recruiting
Diagnosed with Multiple Sclerosis and have a history of relapse
Conditions:
Multiple Sclerosis(MS)
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/21/2024
Locations: Minnesota Center for Multiple Sclerosis Site Number : 8400073, Plymouth, Minnesota
Conditions: Multiple Sclerosis
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
Study details include:
This event... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/20/2024
Locations: Minnesota Center for Multiple Sclerosis Site Number : 8400073, Plymouth, Minnesota
Conditions: Multiple Sclerosis
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
06/14/2024
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Multiple Sclerosis (MS)
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
Recruiting
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/10/2024
Locations: AXIS Clinicals, Dilworth, Minnesota
Conditions: Autoimmune Diseases, Multiple Sclerosis
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.
Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/21/2024
Locations: Minnesota Center Multiple Sclerosis Main Centre, Plymouth, Minnesota
Conditions: Relapsing Multiple Sclerosis
Study to Evaluate Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab
Recruiting
The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd)-enhancing lesions.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2024
Locations: TG Therapeutics Investigational Trial Site, Golden Valley, Minnesota +1 locations
Conditions: Relapsing Multiple Sclerosis
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Recruiting
Primary Objective:
To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)
Secondary Objectives:
To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relations... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/24/2024
Locations: Mayo Clinic Site Number : 8400111, Rochester, Minnesota
Conditions: Primary Progressive Multiple Sclerosis
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Recruiting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.
The TRaditional versus Ear... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Sclerosis, Relapsing-Remitting
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.
All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/26/2024
Locations: University of Minnesota Multiple Sclerosis Center, Minneapolis, Minnesota +1 locations
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Epidural Stimulation in Multiple Sclerosis
Recruiting
A study to quantify changes in motor performance of epidural stimulation in progressive multiple sclerosis (MS) patients over the course of 12 rehabilitation sessions.
Gender:
All
Ages:
22 years and above
Trial Updated:
01/16/2024
Locations: Mayo Clinic, Rochester, Minnesota
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/19/2023
Locations: Mayo Clinic, St. Mary's Campus, Rochester, Minnesota
Conditions: Neurogenic Bladder, Stroke, Multiple Sclerosis, Spinal Cord Injuries (Complete and Incomplete)
A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Recruiting
The primary objective of the study is to estimate the prevalence of major congenital malformations (MCMs) and compare the prevalence between the diroximel fumarate (DRF) and comparator groups. The secondary objectives of the study are to estimate the incidence of spontaneous abortion (SA) and compare the incidence between the DRF and comparator groups; to estimate the incidence of preterm birth and compare the incidence between the DRF and comparator groups; to estimate the incidence of stillbir... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
10/12/2023
Locations: OptumInsight, Eden Prairie, Minnesota
Conditions: Multiple Sclerosis
1 - 12 of 13